Literature DB >> 34479913

MicroRNAs Involved in Small-cell Lung Cancer as Possible Agents for Treatment and Identification of New Targets.

Ulrich H Weidle1, Adam Nopora2.   

Abstract

Small-cell lung cancer, a neuro-endocrine type of lung cancers, responds very well to chemotherapy-based agents. However, a high frequency of relapse due to adaptive resistance is observed. Immunotherapy-based treatments with checkpoint inhibitors has resulted in improvement of treatment but the responses are not as impressive as in other types of tumor. Therefore, identification of new targets and treatment modalities is an important issue. After searching the literature, we identified eight down-regulated microRNAs involved in radiation- and chemotherapy-induced resistance, as well as three up-regulated and four down-regulated miRNAs with impacts on proliferation, invasion and apoptosis of small-cell lung cancer cells in vitro. Furthermore, one up-regulated and four down-regulated microRNAs with in vivo activity in SCLC cell xenografts were identified. The identified microRNAs are candidates for inhibition or reconstitution therapy. The corresponding targets are candidates for inhibition or functional reconstitution with antibody-based moieties or small molecules. Copyright
© 2021, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Apoptosis; chemoresistance; invasion; metastasis; microRNA-based therapy; new treatment modalities; proliferation; review; target identification

Mesh:

Substances:

Year:  2021        PMID: 34479913      PMCID: PMC8441759          DOI: 10.21873/cgp.20283

Source DB:  PubMed          Journal:  Cancer Genomics Proteomics        ISSN: 1109-6535            Impact factor:   4.069


  155 in total

1.  Sequence and expression of seven new tetraspans.

Authors:  V Serru; P Dessen; C Boucheix; E Rubinstein
Journal:  Biochim Biophys Acta       Date:  2000-03-16

2.  MicroRNA-138 Regulates DNA Damage Response in Small Cell Lung Cancer Cells by Directly Targeting H2AX.

Authors:  Huan Yang; Jinwen Luo; Zhiguang Liu; Rui Zhou; Hong Luo
Journal:  Cancer Invest       Date:  2015-02-20       Impact factor: 2.176

Review 3.  Cellular uptake and intracellular trafficking of antisense and siRNA oligonucleotides.

Authors:  Rudolph L Juliano; Xin Ming; Osamu Nakagawa
Journal:  Bioconjug Chem       Date:  2011-10-27       Impact factor: 4.774

4.  Cyclin E2, a novel G1 cyclin that binds Cdk2 and is aberrantly expressed in human cancers.

Authors:  J M Gudas; M Payton; S Thukral; E Chen; M Bass; M O Robinson; S Coats
Journal:  Mol Cell Biol       Date:  1999-01       Impact factor: 4.272

Review 5.  H2AX a promising biomarker for lung cancer: a review.

Authors:  D Matthaios; P Hountis; P Karakitsos; D Bouros; S Kakolyris
Journal:  Cancer Invest       Date:  2013-11       Impact factor: 2.176

6.  Upregulation of the inwardly rectifying potassium channel Kir2.1 (KCNJ2) modulates multidrug resistance of small-cell lung cancer under the regulation of miR-7 and the Ras/MAPK pathway.

Authors:  Huanxin Liu; Jie Huang; Juan Peng; Xiaoxia Wu; Yan Zhang; Weiliang Zhu; Linlang Guo
Journal:  Mol Cancer       Date:  2015-03-12       Impact factor: 27.401

Review 7.  Development of Novel Therapeutic Agents by Inhibition of Oncogenic MicroRNAs.

Authors:  Dinh-Duc Nguyen; Suhwan Chang
Journal:  Int J Mol Sci       Date:  2017-12-27       Impact factor: 5.923

Review 8.  The Regulation and Function of the L-Type Amino Acid Transporter 1 (LAT1) in Cancer.

Authors:  Travis B Salisbury; Subha Arthur
Journal:  Int J Mol Sci       Date:  2018-08-12       Impact factor: 5.923

9.  Loss of LLGL1 Expression Correlates with Diffuse Gastric Cancer and Distant Peritoneal Metastases.

Authors:  Alexander Desuki; Frank Staib; Ines Gockel; Markus Moehler; Hauke Lang; Stefan Biesterfeld; Annett Maderer; Peter R Galle; Martin R Berger; Carl C Schimanski
Journal:  Can J Gastroenterol Hepatol       Date:  2019-04-01

10.  MCL1 inhibition is effective against a subset of small-cell lung cancer with high MCL1 and low BCL-XL expression.

Authors:  Yuto Yasuda; Hiroaki Ozasa; Young Hak Kim; Masatoshi Yamazoe; Hitomi Ajimizu; Tomoko Yamamoto Funazo; Takashi Nomizo; Takahiro Tsuji; Hironori Yoshida; Yuichi Sakamori; Naoki Nakajima; Toshi Menju; Akihiko Yoshizawa; Hiroshi Date; Toyohiro Hirai
Journal:  Cell Death Dis       Date:  2020-03-09       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.